Malaria Treatment Policy Change and Implementation: The Case of Uganda

  • Nanyunja M
  • Nabyonga Orem J
  • Kato F
  • et al.
N/ACitations
Citations of this article
100Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Malaria due to P. falciparum is the number one cause of morbidity and mortality in Uganda where it is highly endemic in 95% of the country. The use of efficacious and effective antimalarial medicines is one of the key strategies for malaria control. Until 2000, Chloroquine (CQ) was the first-line drug for treatment of uncomplicated malaria in Uganda. Due to progressive resistance to CQ and to a combination of CQ with Sulfadoxine-Pyrimethamine, Uganda in 2004 adopted the use of ACTs as first-line drug for treating uncomplicated malaria. A review of the drug policy change process and postimplementation reports highlight the importance of managing the policy change process, generating evidence for policy decisions and availability of adequate and predictable funding for effective policy roll-out. These and other lessons learnt can be used to guide countries that are considering anti-malarial drug change in future.

Cite

CITATION STYLE

APA

Nanyunja, M., Nabyonga Orem, J., Kato, F., Kaggwa, M., Katureebe, C., & Saweka, J. (2011). Malaria Treatment Policy Change and Implementation: The Case of Uganda. Malaria Research and Treatment, 2011, 1–14. https://doi.org/10.4061/2011/683167

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free